Notes: GRL-0617 is an inhibitor of severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 papain-like proteases (PLpros; IC50s = 0.6 and 1.5 µM, respectively).{60299,54467} It increases the viability of SARS-CoV-infected Vero E6 cells (EC50 = 14.5 µM).{60299} GRL-0617 (6.25-50 µM) reduces viral replication in SARS-CoV-2-infected Caco-2 cells.{54467}